Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP4F2 | P78329 | 2/20 | 0.43 |
| ▸ | CYP4A11 | Q02928 | 2/20 | 0.43 |
| ▸ | CYP4Z1 | Q86W10 | 1/20 | 0.37 |
| ▸ | SYK | P43405 | 5/20 | 0.36 |
| ▸ | CASR | P41180 | 3/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.36 |
| ▸ | ADRB2 | P07550 | 2/20 | 0.36 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.36 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.36 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.36 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.36 |
| ▸ | JAK2 | O60674 | 1/20 | 0.36 |
| ▸ | JAK1 | P23458 | 1/20 | 0.36 |
| ▸ | TYK2 | P29597 | 1/20 | 0.36 |
| ▸ | JAK3 | P52333 | 1/20 | 0.36 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.34 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.34 |
| ▸ | P2RY12 | Q9H244 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17318002 | 0.88 | SMN1; SMN2 (0.36) | MEN1GAAKMT2ASMN1; SMN2 | |
| SCHEMBL19031895 | 0.81 | CNR2 (0.38) | MEN1GAAKMT2ASMN1; SMN2 | |
| SCHEMBL16797513 | 0.81 | SMN1; SMN2 (0.36) | MEN1GAAKMT2ASMN1; SMN2 | |
| SCHEMBL17765327 | 0.80 | GAA (0.36) | SYKMEN1GAAKMT2ASMN1; SMN2 | |
| SCHEMBL17318012 | 0.77 | KMT2A (0.34) | MEN1GAAKMT2ASMN1; SMN2 | |
| SCHEMBL18982653 | 0.76 | CYP4F2 (0.43) | CYP4F2CYP4A11CYP4Z1CASRCYP2D6 | |
| SCHEMBL25245034 | 0.76 | CYP4F2 (0.54) | CYP4F2CYP4A11CYP4Z1SYKJAK2 | |
| SCHEMBL31067871 | 0.76 | CYP4F2 (0.54) | CYP4F2CYP4A11CYP4Z1SYKJAK2 | |
| SCHEMBL17768392 | 0.76 | KDM4E (0.37) | MEN1GAAKMT2ASMN1; SMN2 | |
| SCHEMBL14109903 | 0.74 | CYP4F2 (0.54) | CYP4F2CYP4A11CYP4Z1SYKJAK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-108738320-B | cGMP modulators for the treatment of cardiovascular diseases | 默沙东公司 | 2021-11-19 | — | — | CN | disclosed |
| EP-3394067-B1 | 4-AMINO-2-(1H-PYRAZOLO[3,4-B]PYRIDIN-3-YL)-6-OXO-6,7-DIHYDRO-5H-PYRROLO[2,3-D]PYRIMIDINE DERIVATIVES AND THE RESPECTIVE (1H-INDAZOL-3-YL) DERIVATIVES AS CGMP MODULATORS FOR TREATING CARDIOVASCULAR DISEASES | MERCK SHARP & DOHME (US) | 2020-04-01 | — | — | EP | disclosed |
| EP-3394067-B1 | 4-AMINO-2-(1H-PYRAZOLO[3,4-B]PYRIDIN-3-YL)-6-OXO-6,7-DIHYDRO-5H-PYRROLO[2,3-D]PYRIMIDINE DERIVATIVES AND THE RESPECTIVE (1H-INDAZOL-3-YL) DERIVATIVES AS CGMP MODULATORS FOR TREATING CARDIOVASCULAR DISEASES | MERCK SHARP & DOHME (US) | 2020-04-01 | — | — | EP | disclosed |
| US-10428076-B2 | Soluble guanylate cyclase stimulators | MERCK SHARP & DOHME CORP. (US) | 2019-10-01 | — | — | US | disclosed |
| US-10428076-B2 | Soluble guanylate cyclase stimulators | MERCK SHARP & DOHME CORP. (US) | 2019-10-01 | — | — | US | disclosed |
| US-20180305366-A1 | SOLUBLE GUANYLATE CYCLASE STIMULATORS | MERCK SHARP & DOHME CORP. (US) | 2018-10-25 | — | — | US | disclosed |
| US-10030027-B2 | Soluble guanylate cyclase stimulators | MERCK SHARP & DOHME CORP. (US) | 2018-07-24 | — | — | US | disclosed |
| US-10030027-B2 | Soluble guanylate cyclase stimulators | MERCK SHARP & DOHME CORP. (US) | 2018-07-24 | — | — | US | disclosed |
| WO-2017112617-A1 | 4-AMINO-2-(1H-PYRAZOLO[3,4-B]PYRIDIN-3-YL)-6-OXO-6,7-DIHYDRO-5H-PYRROLO[2,3-D]PYRIMIDINE DERIVATIVES AND THE RESPECTIVE (1H-INDAZOL-3-YL) DERIVATIVES AS CGMP MODULATORS FOR TREATING CARDIOVASCULAR DISEASES | MERCK SHARP & DOHME CORP. (US) | 2017-06-29 | — | — | WO | disclosed |
| US-20170174693-A1 | SOLUBLE GUANYLATE CYCLASE STIMULATORS | MERCK SHARP & DOHME LLC | 2017-06-22 | — | — | US | disclosed |
| US-20170174693-A1 | SOLUBLE GUANYLATE CYCLASE STIMULATORS | MERCK SHARP & DOHME LLC | 2017-06-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180305366-A1 | SOLUBLE GUANYLATE CYCLASE STIMULATORS | GUCY1A1, GUCY1A2, PDE2A | CYP4F2 1819/4885CYP4A11 515/4885CYP4Z1 2694/4885 |
| US-20170174693-A1 | SOLUBLE GUANYLATE CYCLASE STIMULATORS | GUCY1A1, GUCY1A2, PDE2A | CYP4F2 1819/4885CYP4A11 515/4885CYP4Z1 2694/4885 |
| US-10030027-B2 | Soluble guanylate cyclase stimulators | GUCY1A1, GUCY1A2, PDE2A | CYP4F2 1819/4885CYP4A11 515/4885CYP4Z1 2694/4885 |
| US-10428076-B2 | Soluble guanylate cyclase stimulators | GUCY1A1, GUCY1A2, PDE2A | CYP4F2 1819/4885CYP4A11 515/4885CYP4Z1 2694/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.